RELEASES
CORPORATE GOVERNANCENEWS RELEASESSEC FILINGSSTOCK INFORMATIONEVENTS AND WEBCASTSPUBLICATIONS AND POSTERSINVESTOR ALERTSINVESTOR INQUIRIES
X
November 22, 2022 9:10 AM
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
The C ompany’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL eventLos Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.’s 2022 KOL Series (Part 8) on Tuesday, November 29, at 11 a.m. EST. The KOL event will focus on the use of monoclonal antibody-based immunotherapies in infectious diseases and Aridis’ Phase 3 ‘ASAP-1’ study that compares the superiority of adjunctive use of the investigational, targeted immunotherapy candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of ventilator associated pneumonia (VAP) caused by Gram-positive bacteria Staphylococcus aureus ( S. aureus ).
The virtual event will feature key opinion leader Professor Bruno Francois, MD, an intensive care medicine specialist and an internationally recognized expert on immunotherapy in infectious diseases who has served as a senior principal investigator in several clinical trials involving monoclonal antibodies. Professor Francois heads the Limoges Clinical Investigation Center with a specific focus on infectious diseases in critically ill patients at the University Hospital of Limoges, France. He has served on numerous advisory boards for Sepsis and VAP multinational trials, independent clinical evaluation committees and adjudication committees. He is also the author of multiple publications and a reviewer for medical journals focused on infectious disease in the ICU.
Vernon T. Bernadino, Managing Director and Senior Healthcare Analyst at H.C. Wainwright & Co. will host and moderate the virtual KOL. Aridis’ Chief Medical Officer Hasan Jafri, MD, and Vu Truong, PhD (CEO) will also participate in the event.
To register for the KOL, please click here.